Cube Pharmaceuticals announced that recently, the company received the “Notice of Acceptance” of the application for clinical trial registration of celecoxib tramadol hydrochloride tablets issued by the State Drug Administration. The acceptance number is CYHL2600101. The specifications are celecoxib 56 mg and tramadol hydrochloride 44 mg. The application was classified into 3 categories of chemicals, and the company was the first domestic clinical enterprise to apply.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.